Table A4.
Fitted Multivariable Cox Proportional Hazards Model for Time to Treatment Failure
| Variable | Coefficient | SE | Relative Risk | P |
|---|---|---|---|---|
| All variables, n = 539 | ||||
| Age | 0.003 | 0.01 | 1.00 | .58 |
| Age2 | 0.001 | 0.0003 | 1.00 | .05 |
| Ln(β-2M) | 0.33 | 0.16 | 1.39 | .03 |
| BM lymphocytes | 0.01 | 0.004 | 1.01 | .01 |
| Regimen = FC/FM (v fludarabine) | −0.37 | 0.15 | 0.69 | .02 |
| Regimen = FCR (v fludarabine) | −1.65 | 0.17 | 0.19 | < .001 |
| Excluding treatment regimen, n = 461 | ||||
| Age | 0.01 | 0.01 | 1.01 | .28 |
| Age2 | 0.001 | 0.0004 | 1.00 | .02 |
| Ln(ALP) | 1.26 | 0.23 | 3.52 | < .001 |
| Ln(blood prolymphocytes) | −0.39 | 0.08 | 0.68 | < .001 |
| BM lymphocytes | 0.01 | 0.005 | 1.01 | .01 |
| Ln(time: diagnosis to treatment) | −0.15 | 0.05 | 0.86 | .01 |
Abbreviations: Age2, age x age; Ln, natural log; β-2M, β2 microglobulin; BM, bone marrow; FC, fludarabine with cyclophosphamide; FM, fludarabine with mitoxantrone; FCR, fludarabine, cyclophosphamide, and rituximab; ALP, alkaline phosphatase.